TY - JOUR
T1 - Multiple Myeloma
T2 - Diagnosis and Treatment
AU - Rajkumar, S. Vincent
AU - Kumar, Shaji
N1 - Publisher Copyright:
© 2016 Mayo Foundation for Medical Education and Research.
PY - 2016/1/1
Y1 - 2016/1/1
N2 - The diagnosis and treatment of multiple myeloma has changed dramatically in the past decade. The disease definition has been updated to include highly specific biomarkers in addition to established markers of end-organ damage. The staging system has been revised to combine both measures of tumor burden and disease biology. Advances in therapy have resulted in a marked improvement in overall survival. New drugs introduced in the past few years include carfilzomib, pomalidomide, panobinostat, ixazomib, elotuzumab, and daratumumab. In this review, we outline the current approach to the diagnosis, prognosis, and management of multiple myeloma.
AB - The diagnosis and treatment of multiple myeloma has changed dramatically in the past decade. The disease definition has been updated to include highly specific biomarkers in addition to established markers of end-organ damage. The staging system has been revised to combine both measures of tumor burden and disease biology. Advances in therapy have resulted in a marked improvement in overall survival. New drugs introduced in the past few years include carfilzomib, pomalidomide, panobinostat, ixazomib, elotuzumab, and daratumumab. In this review, we outline the current approach to the diagnosis, prognosis, and management of multiple myeloma.
UR - http://www.scopus.com/inward/record.url?scp=84952845340&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84952845340&partnerID=8YFLogxK
U2 - 10.1016/j.mayocp.2015.11.007
DO - 10.1016/j.mayocp.2015.11.007
M3 - Review article
C2 - 26763514
AN - SCOPUS:84952845340
SN - 0025-6196
VL - 91
SP - 101
EP - 119
JO - Mayo Clinic proceedings
JF - Mayo Clinic proceedings
IS - 1
ER -